Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
May 12 2020 - 10:00AM
Business Wire
Pfizer Inc. (NYSE: PFE) invites investors and the general public
to listen to a webcast of a discussion with Charles Triano, Senior
Vice President, Investor Relations, at the RBC Capital Markets 2020
Global Healthcare Conference on Tuesday, May 19, 2020 at 11:30 a.m.
EDT.
To listen to the webcast, visit our web site at
www.pfizer.com/investors. Information on accessing and
pre-registering for the webcast will be available at
www.pfizer.com/investors beginning today.
Visitors will be able to listen to an archived copy of the
webcast at www.pfizer.com/investors.
About Pfizer: Breakthroughs That Change Patients’
Lives
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products, including innovative medicines and vaccines. Every day,
Pfizer colleagues work across developed and emerging markets to
advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our
responsibility as one of the world's premier innovative
biopharmaceutical companies, we collaborate with health care
providers, governments and local communities to support and expand
access to reliable, affordable health care around the world. For
more than 150 years, we have worked to make a difference for all
who rely on us. We routinely post information that may be important
to investors on our website at www.Pfizer.com. In addition, to
learn more, please visit us on www.Pfizer.com and follow us on
Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us
on Facebook at Facebook.com/Pfizer.
Disclosure Notice: The webcast may include
forward-looking statements about, among other things, our
anticipated future operating and financial performance, business
plans and prospects, expectations for our product pipeline, in-line
products and product candidates, strategic reviews, capital
allocation objectives, plans for and prospects of our acquisitions
and other business-development activities, including our proposed
transaction with Mylan N.V. (Mylan) to combine Upjohn and Mylan to
create a new global pharmaceutical company, Viatris, our
acquisition of Array BioPharma Inc. and our transaction with GSK
which combined our respective consumer healthcare businesses into a
new consumer healthcare joint venture, benefits anticipated from
the reorganization of our commercial operations in 2019, our
ability to successfully capitalize on growth opportunities or
prospects, manufacturing and product supply, our efforts to respond
to COVID-19, our expectations regarding the impact of COVID-19 on
our business, and plans relating to share repurchases and
dividends, among other things, that are subject to substantial
risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statements. A
description of these risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2019 and in its subsequent reports on Form 10-Q,
including in the sections thereof captioned “Risk Factors” and
“Forward-Looking Information and Factors That May Affect Future
Results”, as well as in its subsequent reports on Form 8-K, all of
which are filed with the U.S. Securities and Exchange Commission
and available at www.sec.gov and www.pfizer.com.
The forward-looking statements in the webcast speak only as of
the original date of the webcast. Pfizer assumes no obligation to
update forward-looking statements contained in the webcast as the
result of new information or future events or developments.
ADDITIONAL INFORMATION
This communication shall not constitute an offer to sell or the
solicitation of an offer to sell or the solicitation of an offer to
buy any securities, nor shall there be any sale of securities in
any jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. No offer of securities
shall be made except by means of a prospectus meeting the
requirements of Section 10 of the Securities Act of 1933, as
amended. In connection with the proposed combination of Upjohn Inc.
(“Newco”), a wholly owned subsidiary of Pfizer Inc. (“Pfizer”) and
Mylan N.V. (“Mylan”), which will immediately follow the proposed
separation of the Upjohn business (the “Upjohn Business”) from
Pfizer (the “proposed transaction”), Newco and Mylan have filed
certain materials with the SEC, including, among other materials,
the Form S-4, Form 10 and Prospectus filed by Newco and the Proxy
Statement filed by Mylan. The Form S-4 was declared effective on
February 13, 2020 and the Proxy Statement and the Prospectus were
first mailed to shareholders of Mylan on or about February 14, 2020
to seek approval of the proposed transaction. The Form 10 has not
yet become effective. After the Form 10 is effective, a definitive
information statement will be made available to the Pfizer
stockholders relating to the proposed transaction. Newco and Mylan
intend to file additional relevant materials with the SEC in
connection with the proposed transaction. INVESTORS AND SECURITY
HOLDERS ARE URGED TO READ DOCUMENTS FILED WITH THE SEC CAREFULLY
AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION ABOUT MYLAN, NEWCO AND THE PROPOSED TRANSACTION. The
documents relating to the proposed transaction (when they are
available) can be obtained free of charge from the SEC’s website at
www.sec.gov. These documents (when they are available) can also be
obtained free of charge from Mylan, upon written request to Mylan
or by contacting Mylan at (724) 514-1813 or
investor.relations@mylan.com or from Pfizer on Pfizer’s internet
website at
https://investors.Pfizer.com/financials/sec-filings/default.aspx or
by contacting Pfizer’s Investor Relations Department at (212)
733-2323, as applicable.
PARTICIPANTS IN THE SOLICITATION
This communication is not a solicitation of a proxy from any
investor or security holder. However, Pfizer, Mylan, Newco and
certain of their respective directors and executive officers may be
deemed to be participants in the solicitation of proxies in
connection with the proposed transaction under the rules of the
SEC. Information about the directors and executive officers of
Pfizer may be found in its Annual Report on Form 10-K filed with
the SEC on February 27, 2020, and its definitive proxy statement
relating to its 2020 Annual Meeting filed with the SEC on March 13,
2020, as supplemented by its supplement to proxy statement filed
with the SEC on April 7, 2020. Information about the directors and
executive officers of Mylan may be found in its Annual Report on
Form 10-K filed with the SEC on February 28, 2020, and its
definitive proxy statement relating to its 2019 Annual Meeting
filed with the SEC on May 24, 2019. Additional information
regarding the interests of these participants can also be found in
the Form S-4, the Proxy Statement and the Prospectus. These
documents can be obtained free of charge from the sources indicated
above.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200512005306/en/
Media Relations:
Amy Rose +1 (646) 592-3157 Amy.Rose@Pfizer.com Investor Relations: Ryan Crowe +1 (212) 733-8160 Ryan.Crowe@Pfizer.com
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024